Physician profile
Ryan J Bowman
NPI 1477766855
$693.34
in general payments reported to CMS, 2019-2025
11 companies · $19.03 in 2025
The $19.03 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.89 · 2020: $48.80 · 2021: $34.48 · 2022: $103 · 2023: $243 · 2024: $200 · 2025: $19.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $461.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $224.49 | 2022-2023 | Urolift |
| Boston Scientific Corporation | $131.59 | 2019-2024 | Rezum Generator |
| Endo Pharmaceuticals INC. | $89.33 | 2019-2023 | Xiaflex |
| Bayer Healthcare Pharmaceuticals INC. | $56.89 | 2022 | |
| Endo USA, INC. | $47.94 | 2024 | Xiaflex |
| Coloplast Corp | $30.73 | 2021-2024 | |
| Procept Biorobotics Corporation | $27.29 | 2024 | Aquabeam System |
| Urogen Pharma, INC. | $26.16 | 2022 | |
| Progenics Pharmaceuticals, INC. | $20.05 | 2024 | |
| Laborie Medical Technologies Corp. | $19.84 | 2020 | |
| Dendreon Pharmaceuticals LLC | $19.03 | 2025 | Provenge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.